Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Acclaimed clinical researcher, Professor Laurent Servais, has been appointed Professor of Paediatric Neuromuscular Diseases at the MDUK Oxford Neuromuscular Centre. The centre is a partnership between Muscular Dystrophy UK (MDUK) and the University of Oxford with the aim of driving research into potential treatments from the lab into the clinic.

Professor Laurent Servais smiling

Professor Servais will join the MDUK Oxford Neuromuscular Centre with a wealth of experience within the neuromuscular field. He has overseen numerous clinical trials to test treatments for Duchenne muscular dystrophy and spinal muscular atrophy (SMA). He is also the leader of the newborn screening program for SMA in southern Belgium. His main research expertise covers the development of innovative outcome measures, including connected devices for real-life patients’ evaluation.

Professor Servais is currently Head of the Institute I-Motion, in Paris, and Head of the Neuromuscular Centre in Liège, Belgium. He is also a Professor of Child Neurology at Liège University. He will cease his activity in Paris, but will keep an affiliation in his hometown hospital and university as an invited Professor.  Professor Servais will start his tenure with the MDUK Oxford Neuromuscular Centre in September 2019 and will relocate to Oxford from Belgium.

Commenting on his appointment, Professor Servais, said:

I’m really pleased to be joining the MDUK Oxford Neuromuscular Centre. It is an exciting time for research as we build our understanding of muscle-wasting conditions and more potential treatments are discovered. I look forward to joining the buoyant department of paediatrics and this team of brilliant and committed scientists, project managers and physicians, and bringing my experience of clinical trial development to the centre to help accelerate the process of bringing new treatments to patients.I am very excited by the challenge to develop a team in such a stimulating human and scientific environment. I also truly believe that there is a high potential synergy between the Centres of Liège and Oxford, and that both sites may benefit from a close collaboration.

Professor Matthew Wood, Director of the MDUK Oxford Neuromuscular Centre and Professor of Neuroscience at the University of Oxford, said:

Laurent’s appointment is a real coup for the centre. With emerging treatments for muscle-wasting conditions on the horizon, the need and demand for clinical trials is greater than ever, but we know that a lack of staff and expertise can lead to fewer trials taking place. Laurent’s experience, particularly of designing and leading innovative clinical trials for Duchenne and SMA, will be invaluable if we are to lead the way in improving how clinical trials are managed and run. Only by doing this can we achieve our urgent goal of bringing new treatments to patients more quickly.

The MDUK Oxford Neuromuscular Centre is housed by the University of Oxford’s Department of Paediatrics and was established in January 2019. It aims to speed up the process of translating scientific research into clinical trials and to improve infrastructure of such trials to make sure more of these take place more cost-effectively. This will in turn help people with muscle-wasting conditions access effective new treatments more quickly than ever before.

Similar stories

Five ways the pandemic has affected routine medical care

Since the beginning of the pandemic, COVID has infected at least a third of the UK population and is estimated to have factored in the deaths of almost 200,000 people in the UK. But critically, COVID has also had a devastating impact on our healthcare systems. While this was expected, new evidence is beginning to reveal the scope of the issue – in particular the effects for people living with long-term health conditions.

Clinical trials for a malaria vaccine start in Mali and Indonesia

Sanaria Inc. announced that two new Phase 2 trials of its pioneering malaria vaccines have started. The first is in 6- to 10-year-old children living in Bancoumana, Mali, a malarious region of West Africa. The second is in Indonesian soldiers based in Sumatra, Indonesia. The soldiers will be deploying for six to nine months this coming August to an intensely malarious district in eastern Indonesia.

Mechanism of expanding bacteria revealed

A new study published in Nature has identified a potential Achilles heel in the protective layers surrounding Gram-negative bacteria that could aid in the development of next-generation antibiotics.

Oxford to receive £7 million to turn bright ideas into global opportunities

The University of Oxford has been awarded more than £7 million, the highest amount of funding given to organisations across the UK, in the latest round of UK Research and Innovation’s (UKRI) Impact Acceleration Account (IAA) funding - aimed at fueling the best, brightest and most disruptive ideas from Uk research institutions.

Discovery of gene involved in chronic pain creates new treatment target

Oxford researchers have discovered a gene that regulates pain sensitisation by amplifying pain signals within the spinal cord, helping them to understand an important mechanism underlying chronic pain in humans and providing a new treatment target.

Oxford's largest ever study into Varicose veins shows need for surgery is linked to genetics

A new international study by Oxford researchers published in Nature Communications establishes for the first time, a critical genetic risk score to predict the likelihood of patients suffering with Varicose veins to require surgery, as well as pointing the way towards potential new therapies.